Skip to main content

ROLE OF ETHICS COMMITTEES

The most costly part of new drug discovery is the three phase clinical research lasting for three to four years involving thousands of human volunteers and investigators in multi locations. Any of these potential drug candidates can be abandoned during the trial period if their adverse drug events are beyond the acceptable limits. 

It is certainly a high risk activity involving millions of dollars and pharmaceutical companies usually make sure that trial reports reaching the regulatory authorities are favourable. No new drug can be approved for marketing without submission of trial reports and their scrutiny by the regulatory authorities. Because of these reasons, the whole operation  of clinical research is highly secretive. 

Apart from top MNCs like Pfizer, GSK, Novartis and Novo Nordisk, there are a large number of contract research organizations engaged in clinical trials in India for the last ten years.


As thousands of human subjects are recruited for each drug trial, the regulatory authorities have a responsibility to monitor the trial locations. And it is for this purpose, the Schedule Y of the Drugs & Cosmetics Act stipulates the existence of an ethics committee at each  trial site.  

But for many years, ethics committees have not been existing or non functional in India. It is this ineffectiveness of ethics committees that embolden the CROs and MNCs to carry out trials illegally endangering the lives of illiterate and  ignorant volunteers.

The decision of the Drug Technical Advisory Board to make registration of ethics committees mandatory at its meeting early last month is in consideration of this state of affairs. There has been several complaints about the non functioning of ethics committees at most of the trial sites. It is this situation that has led to a sharp rise in the number of cases of trial related deaths and injuries in the country during the last five years. 

Currently, ethics committees are constituted by the pharma companies or CROs intending to conduct trials but they are not required to be registered. For starting any clinical trial, the approval of the ethics committee is necessary as without which the DCGI do not permit the study in the country. But the ethics committees are not found to be responsible once the approval is given. No periodic meetings with investigators are called and no critical assessment of data is made. And there is no monitoring of the functioning of the ethics committee by the office of DCGI. 

The need to streamline activities of ethics committees is extremely urgent considering the growing  number of clinical trials taking place in the country. Making registration of ethics committees is an extremely critical step and needs to be strictly enforced without any delay.
Labels:

Comments

Post a Comment

Popular posts from this blog

Registration of herbal trials in CTRI is not mandatory

A trial patient visited the site complaining breathlessness and tachycardia. The investigator advised hospitalization but as subject could not afford the expenses, he refused for admission. Is this an SAE because investigator advised hospitalization? G Praveen Kumar. If the patient was not hospitalized, it does not fall into SAE criteria of hospitalization. However, it appears from your mail that the PI felt that the event was serious enough to admit the subject for treatment. This makes it an “important medical event." As per ICH E2A such event also are considered serious. See the ICH E2A excerpt below: Medical and scientific judgement should be exercised in deciding whether expedited reporting is appropriate in other situations, such as important medical events that may not be immediately life-threatening or result in death or hospitalisation but may jeopardise the patient or may require intervention to prevent one of the other outcomes listed in the defin...
Post a Comment
Read more

Unani medicine research institute to come up in Faridabad

A national research institute of 'Unani' medicine will be set up at a village in Faridabad district, a spokesman of Haryana government said today. The institute, which will provide healthcare facilities in the field of non-communicable diseases, would also include a 120-bedded in-patient department, the spokesman of the Ayush department said. Chief Minister Manohar Lal Khattar has approved a proposal to allot land of Kheri Gujran village for the institute. The institute would be developed as a state-of-the-art research centre with facilities for pre-clinical studies, clinical trials, drug standardisation and cultivation of medicinal plants used in 'Unani' system, the spokesman said. It would also offer facilities such as research and geriatric OPDs, speciality clinics, he said. The institute would have laboratories for bio-chemistry, pathology, radiology and USG, drug standardisation, immunology, pharmacognocy and phytochemistry, besides regimental therapy unit, library...
Post a Comment
Read more

Evidence for Atypical Antipsychotic Drugs Called into Question

Despite massive advertising and booming prescriptions, use and sales, the new atypical antipsychotic medications such as Seroquel and Abilify – used to treat schizophrenia , bipolar disorder, depression and other illnesses – lack sufficient evidence to support their widespread and generalized usage. This according to a new study out of the Stanford University School of Medicine and University of Chicago. In the past decade, atypical antipsychotics have rocketed past many commonly prescribed, but older antidepressant and other psychiatric medications. Although initially touted as having few side effects, followup studies have found that atypical antipsychotics have serious side effects, including significant weight gain that can lead to diabetes and heart disease. “Because these drugs have safety issues, physicians should prescribe them only when they are sure patients will get substantial benefits,” said Randall Stafford, M.D., Ph.D., a Stanford associate pro...
Post a Comment
Read more